Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Familial Cancer Clear all
Completed Phase 2 Interventional Results available

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

NCT03233204
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma, Malignant Glioma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Childhood Malignant Germ Cell Tumor, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Wilms Tumor
Interventions
Olaparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
111
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 18, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

NCT00358956
View directory record Official record
Conditions
Thyroid Cancer
Interventions
ZD6474 (vandetanib)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Little Rock, Arkansas • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 18, 2026, 5:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biology of Osteosarcoma (BOOST) Registry and Biobank

NCT03225872
View directory record Official record
Conditions
Osteosarcoma
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
0 Years and older
Enrollment
362 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 18, 2026, 5:24 PM EDT
Terminated Phase 1 Interventional

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

NCT02536183
View directory record Official record
Conditions
Pediatric Cancer, Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Soft Tissue Sarcomas, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumors
Interventions
Magnetic resonance high intensity focused ultrasound, Lyso-thermosensitive liposomal doxorubicin
Device · Drug
Lead sponsor
AeRang Kim
Other
Eligibility
Up to 30 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 18, 2026, 5:24 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Leveraging Family-Based Assets for Black MSM In House Ball Communities

NCT05071378
View directory record Official record
Conditions
HIV I Infection
Interventions
Our Family, Our Voices
Behavioral
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years to 30 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 18, 2026, 5:24 PM EDT
Completed Phase 2 Interventional

New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma

NCT00001335
View directory record Official record
Conditions
Ewing's Sarcoma, Neuroblastoma, Rhabdomyosarcoma
Interventions
ADR-529, Topotecan, G-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 18, 2026, 5:24 PM EDT
Not yet recruiting Not applicable Interventional

Expanding Genetic Access for Prostate Cancer Survivors

NCT07618520
View directory record Official record
Conditions
Prostate Cancer Patients, Hereditary Cancer, Genetic Testing
Interventions
Print Genetic Education Guide, Digital Guide Genetic Education Guide, Enhanced Usual Care
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 18, 2026, 5:24 PM EDT
Completed Not applicable Interventional

mHealth Family Self-Management

NCT03533049
View directory record Official record
Conditions
Transplantation, Pediatric ALL
Interventions
myFAMI
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 100 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 18, 2026, 5:24 PM EDT
Completed No phase listed Observational

Risk Communication Within Mexican-American Families

NCT00469339
View directory record Official record
Conditions
Breast Cancer, Diabetes, Colon Cancer, Cardiovascular Disease
Interventions
Family Health History
Behavioral
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 18, 2026, 5:24 PM EDT
Recruiting Not applicable Interventional

Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers

NCT06409065
View directory record Official record
Conditions
Cancer
Interventions
Meditation Program
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 18, 2026, 5:24 PM EDT
Withdrawn No phase listed Observational

Oncology Research Information Exchange Network in Improving Genetic Screening Rate in Patients With Cancer

NCT03348137
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Questionnaire Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Sep 18, 2026, 5:24 PM EDT
Completed Not applicable Interventional Results available

Fertility Preservation in Male AYA With Cancer

NCT04268004
View directory record Official record
Conditions
Infertility, Male
Interventions
FP Decision Tool and Discussion
Behavioral
Lead sponsor
Leena Nahata
Other
Eligibility
12 Years to 25 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 18, 2026, 5:24 PM EDT
Completed No phase listed Observational

Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer

NCT00482872
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, flow cytometry, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 18, 2026, 5:24 PM EDT
Terminated Phase 2 Interventional

Reduced Intensity AlloSCT in(CML) With Persistent Disease

NCT00531310
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Reduced Intensity Conditioning, Busulfan and Fludarabine
Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 30 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Sep 18, 2026, 5:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Studies of Patient With FPDMM

NCT03854318
View directory record Official record
Conditions
Inherited Hematological Diseases, Rare Diseases, FPDMM
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Day to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2099
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 18, 2026, 5:24 PM EDT
Completed Not applicable Interventional

Yoga Program for Lung Cancer Patients and Caregivers

NCT02196844
View directory record Official record
Conditions
Lung Cancer
Interventions
Hatha Yoga, Questionnaires, Walk Test
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 18, 2026, 5:24 PM EDT
Completed Phase 2 Interventional

Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma

NCT00008008
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, sargramostim, cyclophosphamide, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
2
States / cities
Paterson, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 18, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

NCT01445418
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
AZ2281 + Carboplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Sep 18, 2026, 5:24 PM EDT
Enrolling by invitation Phase 2 Interventional

Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate

NCT07344220
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg
Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 18, 2026, 5:24 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Identifying Family Members in Need of Support While Caregiving and After Loss

NCT02455505
View directory record Official record
Conditions
Advanced Cancer
Interventions
background questionnaire, bereavement risk screening tool
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 18, 2026, 5:24 PM EDT
Recruiting Phase 1 Interventional

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

NCT05630794
View directory record Official record
Conditions
Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
Interventions
Biopsy Procedure, Biospecimen Collection, Colonoscopy, Dordaviprone Hydrochloride, Questionnaire Administration, Sigmoidoscopy
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 18, 2026, 5:24 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Inherited Risk Evaluation Tool (InheRET): Identifying Patients at Increased Risk for Hereditary Disease

NCT04510896
View directory record Official record
Conditions
Hereditary Cancer-Predisposing Syndrome
Interventions
InheRET, Patient Acceptance, Physician Acceptance Survey
Other
Lead sponsor
InheRET, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Ann Arbor, Michigan • Flint, Michigan • Saginaw, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 18, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

NCT01483144
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Eflornithine, Eflornithine Placebo, Sulindac 150 MG, Sulindac placebo
Drug
Lead sponsor
Cancer Prevention Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
10
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 18, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

NCT06557733
View directory record Official record
Conditions
Colorectal Carcinoma, Familial Adenomatous Polyposis
Interventions
Biopsy Procedure, Biospecimen Collection, EP2/EP4 Antagonist TPST-1495, Esophagogastroduodenoscopy, Gastrointestinal Endoscopy, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Rochester, Minnesota • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 18, 2026, 5:24 PM EDT